MPM BioImpact-backed Aktis Oncology seeks up to $840 million valuation in US IPO

Aktis Oncology is seeking a valuation of as much as $840 million in its U.S. initial public offering, the biotechnology ...

MPM BioImpact-Backed Aktis Seeks $212 Million in US IPO

Aktis Oncology Inc., a clinical-stage biotechnology company focused on using so-called radiopharmaceuticals for treatments, ...
Business Wire

MPM Capital Raises Biotech’s Largest Impact Investment Fund to Help Finance the Fight Against Cancer and Other Diseases

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Today, MPM Capital (“MPM”), one of the world’s leading biotech investment firms, announced that it has raised $850 million for its second Oncology Impact Fund (“OIF ...
Business Wire

MPM Capital Announces the Addition of Detlev Biniszkiewicz, Ph.D. to its Investment Committee

CAMBRIDGE, Mass.--(BUSINESS WIRE)--MPM Capital (MPM), one of the world’s prominent biotech investment firms, has announced the addition of Detlev Biniszkiewicz, Ph.D. to its venture investment team as ...
FierceBiotech

SEMMA THERAPEUTICS ANNOUNCES $44 MILLION IN FUNDING LED BY MPM CAPITAL TO DEVELOP CELL THERAPY FOR TREATING TYPE 1 DIABETES; SIGNS AGREEMENT WITH ...

CAMBRIDGE, Mass. – Semma Therapeutics, a company developing a cell therapy for Type 1 diabetes, announced today that it has closed a $44 million Series A consisting of equity financing and strategic ...
Investopedia

Understanding Marginal Propensity to Import (MPM) and Its Impact

Will Kenton is an expert on the economy and investing laws and regulations. He previously held senior editorial roles at Investopedia and Kapitall Wire and holds a MA in Economics from The New School ...